Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmanogepix in Non-Neutropenic Candidemia
NCT03604705Phase 2Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of fosmanogepix in candidemia and invasive candidiasis, sponsored by Basilea Pharmaceutica. Primary endpoint: Treatment Success at End of Study Treatment (EOST). Started Oct 2018; status: completed.
02
Drugs
fosmanogepix
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT03604705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604705.